Literature DB >> 11896081

The bioavailability of mupirocin in nasal secretions in vitro.

R L R Hill1.   

Abstract

AIM: To determine the bioavailability of mupirocin in human nasal secretions and to assess whether the contents of nasal secretions interact appreciably with this antibiotic.
METHODS: The comparative bioavailability of mupirocin and chlorhexidine in nasal secretions was determined by bioassay after one, four, and eight hours of incubation with pooled secretions from three subjects. The interaction of mupirocin with nasal secretions was characterised by matrix assisted laser desorption time of flight mass spectrometry (MALDI-TOF).
RESULTS: MALDI-TOF analysis showed that mupirocin was not absorbed by the main fraction of pooled nasal secretions and should remain active. In bioassay, mupirocin retained 100% of its antistaphylococcal activity in nasal secretions, whereas chlorhexidine was significantly reduced from 100 mg/litre to 1.5 mg/litre and from 1000 mg/litre to 38.5 mg/litre, irrespective of incubation time.
CONCLUSIONS: The high bioavailability of mupirocin in nasal secretions results from the lack of appreciable molecular interactions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11896081      PMCID: PMC1769620          DOI: 10.1136/jcp.55.3.233

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  13 in total

1.  Automated mass spectrometry: a revolutionary technology for clinical diagnostics.

Authors:  J Leushner; N H Chiu
Journal:  Mol Diagn       Date:  2000-12

2.  Enhanced fungicidal activity of N-chlorotaurine in nasal secretion.

Authors:  M Nagl; C Lass-Flörl; A Neher; A Gunkel; W Gottardi
Journal:  J Antimicrob Chemother       Date:  2001-06       Impact factor: 5.790

3.  Direct acquisition of matrix-assisted laser Desorption/Ionization time-of-flight mass spectra from laser capture microdissected tissues

Authors: 
Journal:  Clin Chem       Date:  2000-09       Impact factor: 8.327

4.  Biochemical investigations of nasal secretions.

Authors:  K Schorn; K Hochstrasser
Journal:  Acta Otorhinolaryngol Belg       Date:  1979

5.  Antibacterial properties of Hibitane.

Authors:  T D Hennessey
Journal:  J Clin Periodontol       Date:  1977-12       Impact factor: 8.728

6.  Elimination of nasal carriage of Staphylococcus aureus with mupirocin ('pseudomonic acid')--a controlled trial.

Authors:  M W Casewell; R L Hill
Journal:  J Antimicrob Chemother       Date:  1986-03       Impact factor: 5.790

7.  Resistance to antiseptics in methicillin and gentamicin resistant Staphylococcus aureus.

Authors:  W Brumfitt; S Dixson; J M Hamilton-Miller
Journal:  Lancet       Date:  1985-06-22       Impact factor: 79.321

8.  The in-vitro activity of povidone-iodinecream against Staphylococcus aureus and its bioavailability in nasal secretions.

Authors:  R L Hill; M W Casewell
Journal:  J Hosp Infect       Date:  2000-07       Impact factor: 3.926

9.  Chlorhexidine inactivation by saliva.

Authors:  F K Spijkervet; J J van Saene; H K van Saene; A K Panders; A Vermey; V Fidler
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1990-04

10.  Elimination of nasal carriage of methicillin-resistant Staphylococcus aureus with mupirocin during a hospital outbreak.

Authors:  R L Hill; G J Duckworth; M W Casewell
Journal:  J Antimicrob Chemother       Date:  1988-09       Impact factor: 5.790

View more
  3 in total

Review 1.  Proteomics for nasal secretion analysis.

Authors:  Begoña Casado
Journal:  Curr Allergy Asthma Rep       Date:  2004-05       Impact factor: 4.806

2.  Topical Drug Delivery for Chronic Rhinosinusitis.

Authors:  Jonathan Liang; Andrew P Lane
Journal:  Curr Otorhinolaryngol Rep       Date:  2012-12-27

3.  Discovery of HIV entry inhibitors via a hybrid CXCR4 and CCR5 receptor pharmacophore-based virtual screening approach.

Authors:  Muhammad Usman Mirza; Atefeh Saadabadi; Michiel Vanmeert; Outi M H Salo-Ahen; Iskandar Abdullah; Sandra Claes; Steven De Jonghe; Dominique Schols; Sarfraz Ahmad; Matheus Froeyen
Journal:  Eur J Pharm Sci       Date:  2020-09-02       Impact factor: 4.384

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.